tissue plasminogen activator

Summary

Summary: A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to PLASMIN. It has fibrin-binding activity and is immunologically different from URINARY PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. EC 3.4.21.68.

Top Publications

  1. doi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
  2. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
  3. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    Stroke 38:1655-711. 2007
  4. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
  5. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    University of Iowa Carver College of Medicine, USA
    Circulation 115:e478-534. 2007
  6. ncbi Intrapleural use of tissue plasminogen activator and DNase in pleural infection
    Najib M Rahman
    UKCRC Oxford Respiratory Trials Unit, Oxford Centre for Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital Site, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 365:518-26. 2011
  7. ncbi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
    W Hacke
    Department of Neurology, University of Heidelberg, Germany
    Lancet 352:1245-51. 1998
  8. ncbi Physiological consequences of loss of plasminogen activator gene function in mice
    P Carmeliet
    Whitehead Institute of Biomedical Research, Cambridge, Massachusetts 02142
    Nature 368:419-24. 1994
  9. ncbi National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate
    Dawn Kleindorfer
    University of Cincinnati College of Medicine, Department of Neurology, 231 Albert Sabin Way ML 0525, Cincinnati, Ohio 45267 0525, USA
    Stroke 39:924-8. 2008
  10. ncbi Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine
    K A Hajjar
    Department of Pediatrics, Cornell University Medical College, New York, New York 10021, USA
    J Biol Chem 273:9987-93. 1998

Detail Information

Publications354 found, 100 shown here

  1. doi Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Werner Hacke
    Department of Neurology, Universitat Heidelberg, Heidelberg, Germany
    N Engl J Med 359:1317-29. 2008
    ..We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke...
  2. ncbi Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
    Kennedy R Lees
    Department of Medicine and Therapeutics, Faculty of Medicine, University of Glasgow, Western Infirmary, Glasgow, UK
    Lancet 375:1695-703. 2010
    Early administration of intravenous recombinant tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome...
  3. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    Stroke 38:1655-711. 2007
    ..The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included...
  4. ncbi Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
    Nils Wahlgren
    Department of Neurology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Lancet 369:275-82. 2007
    ..Under European Union regulations, SITS-MOST was required to assess the safety profile of alteplase in clinical practice by comparison with results in randomised controlled trials...
  5. ncbi Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros
    Harold P Adams
    University of Iowa Carver College of Medicine, USA
    Circulation 115:e478-534. 2007
    ..The intended audience is physicians and other emergency healthcare providers who treat patients within the first 48 hours after stroke. In addition, information for healthcare policy makers is included...
  6. ncbi Intrapleural use of tissue plasminogen activator and DNase in pleural infection
    Najib M Rahman
    UKCRC Oxford Respiratory Trials Unit, Oxford Centre for Respiratory Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital Site, Headington, Oxford OX3 7LJ, United Kingdom
    N Engl J Med 365:518-26. 2011
    ..Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial...
  7. ncbi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
    W Hacke
    Department of Neurology, University of Heidelberg, Germany
    Lancet 352:1245-51. 1998
    ..We have assessed the safety and efficacy of intravenous thrombolysis with alteplase (0.9 mg/kg bodyweight) within 6 h of stroke onset...
  8. ncbi Physiological consequences of loss of plasminogen activator gene function in mice
    P Carmeliet
    Whitehead Institute of Biomedical Research, Cambridge, Massachusetts 02142
    Nature 368:419-24. 1994
    ..Mice with combined t-PA and u-PA deficiency suffer extensive spontaneous fibrin deposition, with its associated effects on growth, fertility and survival...
  9. ncbi National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate
    Dawn Kleindorfer
    University of Cincinnati College of Medicine, Department of Neurology, 231 Albert Sabin Way ML 0525, Cincinnati, Ohio 45267 0525, USA
    Stroke 39:924-8. 2008
    Current US estimates of recombinant tissue plasminogen activator (rt-PA) use have been based either on extrapolation of regional studies or on administrative database estimates, both of which may have inherent biases...
  10. ncbi Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine
    K A Hajjar
    Department of Pediatrics, Cornell University Medical College, New York, New York 10021, USA
    J Biol Chem 273:9987-93. 1998
    b>Tissue plasminogen activator binds to endothelial cells via the calcium-regulated phospholipid-binding protein annexin II, an interaction that is inhibited by the prothrombotic amino acid homocysteine...
  11. ncbi High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor
    A M Thögersen
    Department of Medicine, Clinical Chemistry, and Nutritional Research and Pathology Umeå University Hospital, University of Umea, Sweden
    Circulation 98:2241-7. 1998
    ..So far, there have been no primary prospective studies of PAI-1...
  12. ncbi Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
    Joan Montaner
    Cerebrovascular Unit, Vall d Hebron Hospital, Barcelona, Spain
    Circulation 107:598-603. 2003
    ..Moreover, MMP inhibitors reduce hemorrhagic transformation (HT) after embolic ischemia in tissue plasminogen activator (t-PA)-treated animals...
  13. pmc Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis
    Emily S Sena
    Department of Clinical Neurosciences, University of Edinburgh, Edinburgh, UK
    J Cereb Blood Flow Metab 30:1905-13. 2010
    Thrombolysis with recombinant tissue plasminogen activator (rtPA) improves outcome in animal models of stroke and in clinical trial, but is associated with increased intracranial hemorrhage...
  14. ncbi Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia
    Kiyoshi Tsuji
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA
    Stroke 36:1954-9. 2005
    Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury...
  15. pmc Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein
    Manuel Yepes
    Department of Vascular Biology, Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA
    J Clin Invest 112:1533-40. 2003
    ....
  16. doi Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse
    Jean Christophe Copin
    Division of Neurosurgery, University Hospitals of Geneva, Geneva, Switzerland
    Eur J Neurosci 34:1085-92. 2011
    ..Recombinant tissue plasminogen activator (r-tPA) is the only approved thrombolytic treatment of ischemic stroke but r-tPA is potentially ..
  17. ncbi Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
    P A Barber
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    Neurology 56:1015-20. 2001
    ..Thrombolytic therapy for acute stroke (<3 hours) will not have a major impact on death and dependency unless it is accessible to more patients...
  18. ncbi Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke
    Xiaoying Wang
    Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass, USA
    Stroke 35:2726-30. 2004
    Reperfusion therapy with tissue plasminogen activator (tPA) is a rational therapy for acute ischemic stroke. Properly titrated use of tPA improves clinical outcomes...
  19. pmc Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies
    Rao Muralikrishna Adibhatla
    Department of Neurological Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    CNS Neurol Disord Drug Targets 7:243-53. 2008
    ....
  20. pmc Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice
    Leif R Lund
    Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Copenhagen, Denmark
    EMBO J 25:2686-97. 2006
    ....
  21. doi Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats
    Jie Jen Lee
    Department of Surgery, Mackay Memorial Hospital and Mackay Medical College, Taipei, Taiwan
    J Ethnopharmacol 134:824-30. 2011
    ..to the hospital with acute ischemic stroke are initially considered candidates for the recombinant tissue plasminogen activator (rt-PA). However, rt-PA therapy is still lesser than ideal due to its major side effect of hemorrhaging...
  22. doi The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator
    Karine Wiegler
    Service de Neurologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse
    Cerebrovasc Dis 26:360-6. 2008
    ..We also tested the compatibility of the compound with recombinant tissue plasminogen activator (rtPA), commonly used for intravenous thrombolysis and known to enhance excitotoxicity.
  23. ncbi Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion
    Ivo G Schoots
    Department of Surgery, Academic Medical Center, University of Amsterdam, The Netherlands
    Thromb Haemost 91:497-505. 2004
    ..Circulatory fibrinolysis was enhanced by intravenous administration of recombinant tissue plasminogen activator (rt-PA) or by inhibition of PAI-I by administration of MA-33H1F7...
  24. pmc Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
    Joanna M Wardlaw
    Division of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Lancet 379:2364-72. 2012
    Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely...
  25. pmc Neutralisation of uPA with a monoclonal antibody reduces plasmin formation and delays skin wound healing in tPA-deficient mice
    Annika Jögi
    Finsen Laboratory, Copenhagen University Hospital, Copenhagen Biocenter, Copenhagen, Denmark
    PLoS ONE 5:e12746. 2010
    ..In contrast, individual genetic deficiencies in either uPA or tPA lead to wound healing kinetics with no or only slightly delayed closure of skin wounds...
  26. ncbi Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice
    Julie R Rosenbaum
    Department of Internal Medicine, Yale University School of Medicine, West Haven, Conn, USA
    Stroke 35:e353-5. 2004
    Little is known about informed consent for tissue plasminogen activator (tPA)...
  27. ncbi The role of endogenous versus exogenous tPA on edema formation in murine ICH
    Ruth Thiex
    Department of Neurosurgery, Aachen University, Aachen, Germany
    Exp Neurol 189:25-32. 2004
    ..evolved evacuating the hematoma by stereotaxic injection of a fibrinolytic agent such as recombinant tissue plasminogen activator (rtPA), followed by aspiration of the lysed clot...
  28. pmc Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Cardiovasc Diabetol 10:23. 2011
    Increased plasma plasminogen activator inhibitor-1 (PAI-1) activity and decreased tissue plasminogen activator (tPA) activity could be considered a true component of the metabolic syndrome (MetS) associated with an increased risk of ..
  29. pmc Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke
    Haihao Zhu
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Cereb Blood Flow Metab 30:1137-46. 2010
    Recent studies showed that soluble annexin A2 dramatically increases tissue plasminogen activator (tPA)-mediated plasmin generation in vitro, and reduces thrombus formation in vivo...
  30. ncbi Body temperature and response to thrombolytic therapy in acute ischaemic stroke
    M Millan
    Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Eur J Neurol 15:1384-9. 2008
    To determine the relationship between body temperature (BT), arterial recanalization, functional outcome, and hemorrhagic transformation (HT) of cerebral infarction in patients treated with i.v. tissue plasminogen activator (tPA).
  31. pmc Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis
    Maarten G Lansberg
    Stanford Stroke Center, Stanford University Medical Center, Palo Alto, CA 94304 9705, USA
    Stroke 40:2438-41. 2009
    ..European Cooperative Acute Stroke Study (ECASS-3) demonstrated a benefit of treatment with intravenous tissue plasminogen activator (tPA) for acute stroke in the 3- to 4.5-hour time-window...
  32. ncbi A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke
    E Clarke Haley
    Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA
    Stroke 36:607-12. 2005
    ..This open-label, dose-escalation safety study was conducted to develop initial experience with TNK in the treatment of ischemic stroke...
  33. ncbi Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
    W M Clark
    Oregon Stroke Center, Portland 97201, USA
    JAMA 282:2019-26. 1999
    ..This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset...
  34. ncbi Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis
    J M Wardlaw
    Department of Clinical Neurosciences, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Stroke 34:1437-42. 2003
    Recombinant tissue plasminogen activator (rtPA; Actilyse) is not as widely used in clinical practice as it could be. Have new data since 1995 strengthened the evidence sufficiently to justify more widespread use of rtPA?
  35. ncbi Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior
    Robert Pawlak
    Laboratory of Neurobiology and Genetics, The Rockefeller University, 1230 York Avenue, New York, New York 10021, USA
    Nat Neurosci 6:168-74. 2003
    ..These studies support the idea that tPA is critical for the development of anxiety-like behavior after stress...
  36. ncbi Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush
    Lisa B Siconolfi
    Department of Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Neurosci Res 74:430-4. 2003
    ..These findings show that the PAs are important for MMP-9 and MMP-2 activity at the crush site...
  37. pmc Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia
    Wenlan Liu
    College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    Stroke 40:2526-31. 2009
    A major limitation of tissue plasminogen activator (tPA) thrombolysis for ischemic stroke is the narrow time window for safe and effective therapy...
  38. ncbi Tissue-type plasminogen activator: a historical perspective and personal account
    D Collen
    Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    J Thromb Haemost 2:541-6. 2004
    ..Genetically modified variants of t-PA have been developed for bolus administration in patients with AMI...
  39. ncbi NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity
    A Baron
    INSERM U, Cyceron, University of Caen Basse Normandie, Caen, France
    Cell Death Differ 17:860-71. 2010
    ..This study shows that the earlier described pro-neurotoxic effect of tPA is mediated by NR2D-containing NMDAR-dependent extracellular signal-regulated kinase activation, a deleterious effect prevented by synaptic pre-activation...
  40. ncbi Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene
    Joan Montaner
    Neurovascular Research Laboratory, Stroke Unit, Vall d Hebron Hospital, Barcelona, Spain
    Stroke 34:2851-5. 2003
    ..barrier disruption, has been implicated in the appearance of hemorrhagic transformation (HT) after tissue plasminogen activator (tPA) treatment in stroke patients...
  41. ncbi Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats
    Toshihisa Sumii
    Neuroprotection Research Laboratory, Department of Neurology, Massachusetts General Hospital, Charlestown 02129, USA
    Stroke 33:831-6. 2002
    Thrombolytic therapy with tissue plasminogen activator (tPA) for acute ischemic stroke remains complicated by risks of hemorrhagic transformation...
  42. ncbi Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study
    A R Folsom
    Division of Epidemiology, School of Public Health, University of Minnesota, MN 55454-1015, USA
    Arterioscler Thromb Vasc Biol 21:611-7. 2001
    ..of middle-aged adults, we examined the association of incident CHD with several fibrinolytic factors: tissue plasminogen activator antigen, plasminogen activator inhibitor-1, plasminogen, and fibrin fragment D-dimer as well as a ..
  43. pmc Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator
    T H Bugge
    Division of Developmental Biology, Children s Hospital Research Foundation, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 93:5899-904. 1996
    ....
  44. ncbi Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator
    Xiaoying Wang
    Neuroprotection Research Laboratory, Departments of Radiology and Neurology, Massachusetts General Hospital, Charlestown, and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 9:1313-7. 2003
    Although thrombolysis with tissue plasminogen activator (tPA) is a stroke therapy approved by the US Food and Drug Administration, its efficacy may be limited by neurotoxic side effects...
  45. ncbi Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity
    Petti T Pang
    Section on Neural Development and Plasticity, Laboratory of Cellular and Synaptic Neurophysiology, National Institute of Child Health and Human Development NICHD, Bethesda, MD 20892, USA
    Science 306:487-91. 2004
    ..Two secretory proteins, tissue plasminogen activator (tPA) and brain-derived neurotrophic factor (BDNF), have been implicated in this process, but their ..
  46. ncbi Stroke research priorities for the next decade--A representative view of the European scientific community
    Stephen Meairs
    Neurologische Klinik, Ruprecht Karls Universitat Heidelberg, Theodor Kutzer Ufer, DE 68135 Mannheim Germany
    Cerebrovasc Dis 22:75-82. 2006
  47. ncbi Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors
    Maarten G Lansberg
    Stanford University, Stanford Stroke Center, Palo Alto, CA 94304, USA
    Cerebrovasc Dis 24:1-10. 2007
    ....
  48. pmc Inhibition of p75 neurotrophin receptor attenuates isoflurane-mediated neuronal apoptosis in the neonatal central nervous system
    Brian P Head
    Department of Anesthesiology, University of California, San Diego, La Jolla, California, USA
    Anesthesiology 110:813-25. 2009
    ..proBDNF is cleaved into mature BDNF (mBDNF) by plasmin, a protease converted from plasminogen by tissue plasminogen activator (tPA) that is released with neuronal activity; mBDNF supports survival and stabilizes synapses through ..
  49. doi Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic
    Manuel Yepes
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322, USA
    Trends Neurosci 32:48-55. 2009
    ..Here, the best studied pathways of tPA neurotoxicity are discussed along with future directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stroke...
  50. ncbi Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice
    N Nagai
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Center for Molecular and Vascular Biology, KU Leuven, Belgium
    Circulation 99:2440-4. 1999
    ....
  51. ncbi The human tissue plasminogen activator-Cre mouse: a new tool for targeting specifically neural crest cells and their derivatives in vivo
    Thomas Pietri
    UMR 144 Compartimentation et Dynamique Cellulaire Centre National de la Recherche Scientifique et Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Dev Biol 259:176-87. 2003
    ..We have established a new transgenic line expressing the Cre recombinase under the control of the human tissue plasminogen activator promoter (Ht-PA)...
  52. ncbi Fibrinolysis: the key to new pathogenetic mechanisms
    Esther Zorio
    Hospital Universitario La Fe, Centro de Investigacion, Servicio de Cardiología y Servicio de Ginecología Valencia, Spain
    Curr Med Chem 15:923-9. 2008
    ....
  53. ncbi Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II
    Chia Jen Siao
    Department of Pharmacological Sciences and Program in Molecular and Cellular Pharmacology, University Medical Center at Stony Brook, Stony Brook, New York 11794 8651, USA
    J Neurosci 22:3352-8. 2002
    ..One molecule whose expression is upregulated after excitotoxic injury is tissue plasminogen activator (tPA), a serine protease with dual roles in the CNS...
  54. doi Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain
    Toru Yamashita
    Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    J Cereb Blood Flow Metab 29:715-25. 2009
    In the ischemic brain, reperfusion with tissue plasminogen activator (tPA) sometimes causes catastrophic hemorrhagic transformation (HT); however, the mechanism remains elusive...
  55. ncbi Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group
    D Woo
    Department of Neurology, University of Cincinnati, Cincinnati, Ohio 45220, USA
    Stroke 30:2355-9. 1999
    ..Of 42 possible points, 7 points are directly related to measurement of language compared with only 2 points related to neglect...
  56. ncbi Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy
    J P Collet
    Department of Cardiology, Hemostasis Laboratory, Pitie Salpetriere Hospital, Hotel Dieu Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 20:1354-61. 2000
    ..A dynamic study of FITC-recombinant tissue plasminogen activator distribution within the fibrin matrix during the course of fibrinolysis showed that the binding front ..
  57. ncbi Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke
    P A Lapchak
    Department of Neuroscience, University of California at San Diego, La Jolla 92093 0624, USA
    Stroke 31:3034-40. 2000
    A potentially dangerous side effect associated with tissue plasminogen activator (tPA) use is cerebral hemorrhage. We have focused on developing drugs that could be administered with tPA to reduce the rate of hemorrhage...
  58. doi Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Ave, Room 47 123 CHS, Los Angeles, CA 90095 1679, USA
    Circulation 121:879-91. 2010
    ..We sought to examine age-related differences in characteristics, performance measures, temporal trends, and early clinical outcomes for acute ischemic stroke in a large contemporary cohort...
  59. ncbi Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
    V Larrue
    Department of Neurology, University of Toulouse, Toulouse, France
    Stroke 32:438-41. 2001
    Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) improves the outcome for ischemic stroke patients who can be treated within 3 hours of symptom onset...
  60. pmc Methodology of the Interventional Management of Stroke III Trial
    Pooja Khatri
    Department of Neurology, University of Cincinnati, 231 Albert Sabin Way ML 0525, Cincinnati, OH 45267 0525, USA
    Int J Stroke 3:130-7. 2008
    ..a.) approach to recanalization may be more effective than standard i.v. rt-PA (Activase) alone for moderate-to-large National Institutes of Health Stroke Scale (NIHSS>or=10) strokes, and with a similar safety profile...
  61. ncbi Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage
    Violeta Lukic-Panin
    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
    Curr Neurovasc Res 7:319-29. 2010
    One of the therapeutics for acute cerebral ischemia is tissue plasminogen activator (t-PA). Using t-PA after 3 hour time window increases the chances of hemorrhage, involving multiple mechanisms...
  62. ncbi Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease
    Joo Yong Lee
    Asan Institute for Life Science, Department of Neurology, University of Ulsan College of Medicine, Seoul 138 736, Republic of Korea
    Neurosci Lett 423:82-7. 2007
    Although the tissue plasminogen activator (tPA)/plasminogen/plasmin proteolytic system is thought to modulate the catabolism of amyloid-beta (Abeta), in vivo evidence remains insufficient...
  63. doi Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization
    Navdeep Sangha
    Department of Neurology, University of Texas Medical School at Houston, Houston, Texas 77030, USA
    J Stroke Cerebrovasc Dis 21:917.e5-8. 2012
    ..4 seconds. Recanalization of the middle cerebral artery with intravenous tissue plasminogen activator was apparent on digital subtraction angiography, and there was no evidence of intracerebral hemorrhage ..
  64. doi Study on construction of nano tPA plasmid to prevent thrombosis after mechanical valve replacement in dogs
    Shangyi Ji
    Shenzhen Sun Yat sen Cardiovascular Hospital, Shenzhen Heart Institute, Guangdong, China
    J Surg Res 168:e1-5. 2011
    ..Mechanical valve is inclined to induce thrombosis. We intend to elucidate the transfection of nano tissue-type plasminogen activator (tPA) gene plasmid to prevent thrombosis after tricuspid mechanical valve replacement in dogs...
  65. doi Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction
    Waqas Ahmed
    Department of Biosciences, COMSATS Institute of Information Technology, Park Road, Islamabad, 45600, Pakistan
    Mol Biol Rep 38:2541-8. 2011
    ..72, OR=3.7 (95% CI=1.71-8.18)) and lower HDL levels (P<0.05) were found to be significantly associated with the disease. In conclusion the PAI-1 gene polymorphism was found to have a gender specific role in the female MI patients...
  66. ncbi Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke
    Svetlna Pundik
    The Neurological Institute of University Hospitals of Cleveland, Case Medical Center, Cleveland, Ohio, USA
    J Stroke Cerebrovasc Dis 17:266-72. 2008
    ..However, it is unclear whether age over 80 years is a predictor for hemorrhagic transformation after intravenous, intra-arterial, or a combination of both thrombolytic therapies...
  67. ncbi An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus
    S E Tsirka
    Department of Pharmacology, University Medical Center at Stony Brook, New York 11794 8651, USA
    J Neurosci 17:543-52. 1997
    Mice lacking the serine protease tissue plasminogen activator (tPA) are resistant to excitotoxin-mediated hippocampal neuronal degeneration. We have used genetic and cellular analyses to study the role of tPA in neuronal cell death...
  68. ncbi Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces
    Mark A Hancock
    Department of Biochemistry, Queen s University, Kingston, Ontario K7L 3N6, Canada
    J Biol Chem 278:23260-9. 2003
    ..Lp(a) may interfere with tissue plasminogen activator (tPA)-mediated plasminogen activation in fibrinolysis, thereby generating a hypercoagulable state in ..
  69. doi Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors
    David Pineda
    Cancer Research Programme, IMIM Hospital del Mar, C Dr Aiguader 88, 08003 Barcelona, Spain
    Glia 60:526-40. 2012
    ..b>Tissue plasminogen activator (tPA) is a serine protease which best-known function is fibrinolysis, but it is also involved in many ..
  70. doi A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND)
    Henry Ma
    National Stroke Research Institute, Florey Neuroscience Institutes, Austin Health, University of Melbourne, Heidelberg Heights, Victoria, Australia
    Int J Stroke 7:74-80. 2012
    Thrombolytic therapy with tissue plasminogen activator is effective for acute ischaemic stroke within 4·5 h of onset. Patients who wake up with stroke are generally ineligible for stroke thrombolysis...
  71. doi TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after s
    Svetlana Lorenzano
    Unità di Trattamento Neurovascolare, Department of Neurological Sciences, Policlinico Umberto I Sapienza University, Viale del Policlinico 155, 00161 Rome, Italy
    Int J Stroke 7:250-7. 2012
    ..This article describes the design of the Thrombolysis in Elderly Stroke Patients in Italy (TESPI) trial planned to fill the lack of controlled data on i.v. thrombolysis in this age category of stroke patients...
  72. doi Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding
    Jane Maguire
    School of Medicine and Public Health, Faculty of Health, University of Newcastle, Callaghan, New South Wales, Australia
    J Stroke Cerebrovasc Dis 20:134-44. 2011
    ..in platelet glycoprotein Ibα (GPIbα) rs224309 and rs6065, glycoprotein IIIa (GPIIIa) rs5918, tissue plasminogen activator (tPA) rs63020761, plasminogen activating inhibitor (PAI-1) rs72578597, and cyclooxygenase-2 (COX-2) ..
  73. ncbi Body temperature and outcome after stroke thrombolysis
    L Ernon
    Department of Neurology, University Hospital of Leuven, Leuven, Belgium
    Acta Neurol Scand 114:23-8. 2006
    We studied whether baseline body temperature and temperature increases after stroke adversely affect outcome after thrombolysis with intravenous tissue plasminogen activator (IV tPA).
  74. ncbi Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years
    D Kim
    University of California at Los Angeles Stroke Center, Department of Neurology, UCLA Medical Center, Los Angeles, CA, USA
    AJNR Am J Neuroradiol 28:159-63. 2007
    ..The purpose of this study was to compare the baseline characteristics, complications, and outcomes between intra-arterially treated ischemic stroke patients aged > or = 80 years and their younger counterparts...
  75. ncbi Intrapleural tissue plasminogen activator for complicated pleural effusions
    Dionne A Skeete
    Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Trauma 57:1178-83. 2004
    This study is aimed at evaluating the safety and efficacy of intrapleural tissue plasminogen activator (TPA) for complicated pleural effusions, including posttraumatic hemothorax.
  76. ncbi A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units
    C Longstaff
    Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK
    J Thromb Haemost 2:1416-21. 2004
    ..of a range of plasminogen activators (PAs) used as thrombolytic agents, including streptokinase, tissue plasminogen activator (tPA) and variants, and urokinase (uPA), both single and two chain forms...
  77. pmc Intravenous tissue plasminogen activator and stroke in the elderly
    W T Longstreth
    Department of Neurology, University of Washington, Seattle, 98195, USA
    Am J Emerg Med 28:359-63. 2010
    ..in 1995 of the National Institute of Neurological Disorders and Stroke (NINDS) trial of intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke, the benefit and frequency of use of IV tPA in the elderly have ..
  78. ncbi Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain
    Chen Zhang
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Cereb Blood Flow Metab 29:1946-54. 2009
    ..The results of our study indicate that the interaction between tPA and microglial LRP1 increases MMP-9 expression and activity resulting in the degradation of claudin-5 and development of cerebral edema...
  79. ncbi Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid
    James A S Muldowney
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 6300, USA
    Thromb Haemost 97:263-71. 2007
    ..These studies suggest that thrombin-stimulated t-PA release is Galphaq-, PLC-beta-, IP3-, and 5,6-EET-dependent while being prostacyclin-, NO- and K+ channel-independent in HMECs...
  80. ncbi Modulation of the expression of tissue plasminogen activator and its inhibitor by hypoxia in human peritoneal and adhesion fibroblasts
    Ghassan M Saed
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, and the C S Mott Center for Human Growth and Development, Wayne State University, Detroit, Michigan 48201, USA
    Fertil Steril 79:164-8. 2003
    To determine whether normal peritoneal and adhesion fibroblasts express tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI-I) and whether their expression is regulated by oxygen.
  81. ncbi Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
    Stephen M Davis
    Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Australia
    Lancet Neurol 7:299-309. 2008
    Whether intravenous tissue plasminogen activator (alteplase) is effective beyond 3 h after onset of acute ischaemic stroke is unclear...
  82. doi Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production
    Seok Joon Won
    Neurology and Rehabilitation Service, San Francisco Veterans Affairs Medical Center and Department of Neurology, University of California at San Francisco, CA, USA
    Ann Neurol 70:583-90. 2011
    Risk of intracerebral hemorrhage is the primary factor limiting use of tissue plasminogen activator (tPA) for stroke...
  83. pmc Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice
    Melissa Noel
    Laboratory of Neurobiology and Genetics, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:5069-74. 2011
    ..Because tissue plasminogen activator (tPA) has been implicated in neurodegeneration, we examined whether it mediates FAS...
  84. ncbi Sustained benefit of a community and professional intervention to increase acute stroke therapy
    Lewis B Morgenstern
    Stroke Program, Department of Neurology, The University of Texas Medical School at Houston, USA
    Arch Intern Med 163:2198-202. 2003
    ..The ultimate test of an educational intervention is the sustainability of the effect after the intervention ceases...
  85. ncbi Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study
    Harlan M Krumholz
    Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Conn 06520 8088, USA
    Am Heart J 146:839-47. 2003
    ....
  86. pmc Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial
    E Clarke Haley
    Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
    Stroke 41:707-11. 2010
    ..If promise was established, then the trial would continue as a Phase III efficacy trial comparing the selected tenecteplase dose to standard rtPA...
  87. ncbi Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study
    Edward C Jauch
    Department of Emergency Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0769, USA
    Stroke 37:2508-13. 2006
    ..Serum samples from the National Institute for Neurological Disorders and Stroke (NINDS) recombinant tissue plasminogen activator Stroke Study were analyzed for the presence of 4 biochemical markers of neuronal, glial, and ..
  88. pmc Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive
    Nishant K Mishra
    Acute Stroke Unit, University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary and Faculty of Medicine, University of Glasgow, Glasgow G11 6NT, UK
    BMJ 341:c6046. 2010
    ..To assess effect of age on response to alteplase in acute ischaemic stroke...
  89. ncbi Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
    Werner Hacke
    Medical University at Heidelberg, Germany
    Lancet 363:768-74. 2004
    Quick administration of intravenous recombinant tissue plasminogen activator (rt-PA) after stroke improved outcomes in previous trials. We aimed to analyse combined data for individual patients to confirm the importance of rapid treatment.
  90. pmc Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus
    Ramiro Echeverry
    Department of Neurology and Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Clin Invest 120:2194-205. 2010
    ..These data show that tPA can act as an endogenous neuroprotectant in the murine hippocampus...
  91. ncbi Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator
    David M Johnson
    Department of Neurosurgery, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Stroke 36:e53-5. 2005
    ..The authors present the first successful administration of intra-arterial cerebral tissue plasminogen activator to treat an embolic cerebral vascular accident in a 37-week parturient resulting in complete recovery ..
  92. ncbi Neural stem cells rescue nervous purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets
    Jianxue Li
    Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:7839-48. 2006
    ..We previously identified in nr cerebellum a 10-fold increase in tissue plasminogen activator (tPA) as a key component of the mechanism causing nr PN death...
  93. ncbi Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits
    F W Asselbergs
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
    J Thromb Haemost 5:313-20. 2007
    ..was to examine the correlations between plasma levels of plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) and cardiovascular disease-related traits in a general population and whether these correlations ..
  94. ncbi The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1
    Taku Nagai
    Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920 1192, Japan
    J Neurosci 26:12374-83. 2006
    ..Here we show that the tissue plasminogen activator (tPA)-plasmin system regulates nicotine-induced reward and dopamine release by activating protease ..
  95. pmc Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells
    Mariano Hurtado
    Unitat de Recerca Biomedica, Institut de Recerca, Hospital Vall d Hebron, Pg Vall d Hebron 119 129, Barcelona 08035, Spain
    Gut 56:1266-74. 2007
    b>Tissue plasminogen activator (tPA) is the major activator of plasminogen in plasma. This serine protease is overexpressed by exocrine pancreas tumour cells, where it promotes tumour cell proliferation, growth, and invasion...
  96. ncbi Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator
    Tomoaki Murakami
    Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Sakyo ku, Kyoto 606 8507, Japan
    Am J Ophthalmol 143:171-3. 2007
    To evaluate the integrity of photoreceptors in macular edema (ME) associated with branch retinal vein occlusion after intravitreal tissue plasminogen activator.
  97. ncbi Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity
    Geraldine Liot
    INSERM, INSERM Avenir tPA in the working brain, Caen, France Université de Caen Basse Normandie, Caen, France GIP Cyceron, Caen, France
    J Neurochem 98:1458-64. 2006
    ....
  98. ncbi The role of tissue plasminogen activator in methamphetamine-related reward and sensitization
    Taku Nagai
    Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsuruma cho, Showa Ku, Nagoya 466 8560, Japan
    J Neurochem 92:660-7. 2005
    In the central nervous system, tissue plasminogen activator (tPA) plays a role in synaptic plasticity and remodeling. Our recent study has suggested that tPA participates in the rewarding effects of morphine by regulating dopamine release...
  99. ncbi The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context
    Folkert W Asselbergs
    Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands
    Hum Genet 122:275-81. 2007
    ..The present study emphasizes the importance of including environmental factors in genetic analyses to fully comprehend the genetic architecture of a specific trait...
  100. ncbi Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome
    K Kikuchi
    Gastroenterology Hepatology Section and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and the University of Washington School of Medicine, Seattle, WA, USA
    Bone Marrow Transplant 29:329-33. 2002
    ..Prognosis depended on the severity of the underlying VOD and not PVT per se, suggesting that treatments directed solely toward dissolution of portal vein thrombi should be used with caution in this setting...
  101. pmc Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population
    J A Schoenhard
    Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical School, Nashville, TN, USA
    Hum Genet 124:479-88. 2008
    ....

Research Grants83

  1. Action of Fucoidan during the Activation of Plasminogen
    Vasant Doctor; Fiscal Year: 2001
    Considerable attention has been focused recently on the therapeutic value of tissue plasminogen activator (t-PA) as a thrombolytic agent for the treatment of heart attacks and strokes...
  2. Specialized Program of Translational Research In Acute Stroke at the Partners
    Karen Furie; Fiscal Year: 2006
    ..cell death, NBO may be a useful adjunctive therapy that extends the narrow (3-hour) time window for IV tissue plasminogen activator (tPA) therapy...
  3. Specialized Program of Translational Research In Acute Stroke at the Partners
    Karen Furie; Fiscal Year: 2009
    ..cell death, NBO may be a useful adjunctive therapy that extends the narrow (3-hour) time window for IV tissue plasminogen activator (tPA) therapy...
  4. Specialized Program of Translational Research In Acute Stroke at the Partners
    Karen Furie; Fiscal Year: 2007
    ..cell death, NBO may be a useful adjunctive therapy that extends the narrow (3-hour) time window for IV tissue plasminogen activator (tPA) therapy...
  5. Antiphospholipid antibodies and lupus: new molecular targets for treatment
    Silvia S Pierangeli; Fiscal Year: 2010
    ..There is strong evidence that annexin A2, a receptor for tissue plasminogen activator (tPA) and plasminogen, and toll-like receptor 4 (TLR-4), a receptor for bacterial lipopolysaccharide (..
  6. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2007
    ..protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  7. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2005
    ..protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  8. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2004
    ..protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  9. Clotting genetic variant, hormones and venous thrombosis
    Nicholas Smith; Fiscal Year: 2006
    ..protein C receptor, protein S, antithrombin III, tissue activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (TPA), and factors VIII, IX, X, and XlII A and B...
  10. Stroke Disparities Program
    Chelsea Kidwell; Fiscal Year: 2009
    ..significantly increase the number of ischemic stroke patients appropriately treated with intravenous tissue plasminogen activator (IV tPA) in a predominantly underserved community...
  11. Stroke Disparities Program
    Chelsea Kidwell; Fiscal Year: 2007
    ..significantly increase the number of ischemic stroke patients appropriately treated with intravenous tissue plasminogen activator (IV tPA) in a predominantly underserved community...
  12. Stroke Disparities Program
    Chelsea Kidwell; Fiscal Year: 2009
    ..significantly increase the number of ischemic stroke patients appropriately treated with intravenous tissue plasminogen activator (IV tPA) in a predominantly underserved community...
  13. KRINGLE DOMAINS IN BLOOD COAGULATION PROTEINS
    David Roth; Fiscal Year: 1991
    ..a highly conserved structure found in five proteins involved in hemostasis: prothrombin, plasminogen, tissue plasminogen activator, urokinase and Factor XII...
  14. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert A Knight; Fiscal Year: 2010
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) acts to increase blood flow to the ischemic tissue and is the only approved treatment for acute ..
  15. MRI of Acute Vascular Injury and Hemorrhagic Transformation in Ischemic Stroke
    Robert Knight; Fiscal Year: 2009
    ..Thrombolytic therapy with tissue plasminogen activator (tPA) acts to increase blood flow to the ischemic tissue and is the only approved treatment for acute ..
  16. Role of PAI-1 in Venous THrombosis
    Thomas Wakefield; Fiscal Year: 2009
    ..It inactivats both tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA)...
  17. S-Nitrosylated Hemoglobin and Ischemic Brain Injury
    David Warner; Fiscal Year: 2010
    ..It is known from humans treated with tissue plasminogen activator that ischemic tissue can be salvaged from infarction by thrombolytic CBF restoration...
  18. S-Nitrosylated Hemoglobin and Ischemic Brain Injury
    David Warner; Fiscal Year: 2009
    ..It is known from humans treated with tissue plasminogen activator that ischemic tissue can be salvaged from infarction by thrombolytic CBF restoration...
  19. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2009
    ..contrast agents (UCA) potentiate the effect of sonothrombolysis, without or in combination with tissue Plasminogen Activator (tPA)...
  20. Transcranial Sonothrombolysis with Diagnostic Ultrasound
    Thilo Hoelscher; Fiscal Year: 2010
    ..contrast agents (UCA) potentiate the effect of sonothrombolysis, without or in combination with tissue Plasminogen Activator (tPA)...
  21. ROLE OF HISTIDINE-RICH GLYCOPROTEIN IN HEMOSTASIS
    William Morgan; Fiscal Year: 1991
    ..with antithrombin III and heparin cofactor II for heparin, and the activation of plasminogen by tissue plasminogen activator is enhanced by HRG in the presence of fibrinogen or thrombospondin...
  22. PLATELETS, PLATELET AGGREGATES & PLASMINOGEN ACTIVATION
    Joseph Loscalzo; Fiscal Year: 1990
    ..We have demonstrated in preliminary work that tissue plasminogen activator added to platelets induced to aggregate in plasma facilitates dispersal of the aggregates, or ..
  23. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The demonstration that recombinant tissue plasminogen activator (rtPA) is useful for acute management is changing the approach to ischemic stroke...
  24. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2001
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory ..
  25. PATHOPHYSIOLOGY OF CHRONIC CEREBRAL VASOSPASM
    Bryce Weir; Fiscal Year: 1999
    ..Treatment of vasospasm, that includes calcium-channel antagonists, hemodynamic therapy and tissue plasminogen activator, accounts for some of the discrepancy between the number of patients with vasospasm seen ..
  26. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2000
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory ..
  27. Interaction of Estrogen and Tissue Plasminogen Activator
    Shaohua Yang; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The demonstration that recombinant tissue plasminogen activator (rtPA) is useful for acute management is changing the approach to ischemic stroke...
  28. PATHOPHYSIOLOGY OF CHRONIC CEREBRAL VASOSPASM
    Robert MacDonald; Fiscal Year: 2000
    ..Treatment of vasospasm, that includes calcium-channel antagonists, hemodynamic therapy and tissue plasminogen activator, accounts for some of the discrepancy between the number of patients with vasospasm seen ..
  29. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 2000
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory ..
  30. ENDOTHELIAL CELL DIVERSITY DURING FETAL DEVELOPMENT
    Eugene Levin; Fiscal Year: 1999
    ..Using tissue plasminogen activator (tPA) expression as an endothelial cell marker, we have found a pattern of progressive and transitory ..
  31. LEUKOCYTE ADHESION RECEPTORS AND THROMBOSIS IN STROKE
    David Pinsky; Fiscal Year: 2000
    ..the PAI-1 gene are relatively resistant to ischemic cerebral injury, in contrast to mice lacking the tissue plasminogen activator (tPA)gene...
  32. LEUKOCYTE ADHESION RECEPTORS AND THROMBOSIS IN STROKE
    David Pinsky; Fiscal Year: 2001
    ..the PAI-1 gene are relatively resistant to ischemic cerebral injury, in contrast to mice lacking the tissue plasminogen activator (tPA)gene...
  33. LEUKOCYTE ADHESION RECEPTORS AND THROMBOSIS IN STROKE
    David Pinsky; Fiscal Year: 1999
    ..the PAI-1 gene are relatively resistant to ischemic cerebral injury, in contrast to mice lacking the tissue plasminogen activator (tPA)gene...
  34. STRUCTURE/FUNCTION STUDIES ON PLASMINOGEN AND PLASMIN
    Francis Castellino; Fiscal Year: 1999
    ..enzymology, immunochemistry, spectroscopic properties and molecular biology of human plasminogen, tissue plasminogen activator, urokinase, streptokinase and fibrin(ogen)...
  35. Translation of pH-weighted MRI to Image Human Acute Stroke
    ALMA SORENSEN; Fiscal Year: 2009
    ..For instance, the conventional treatment window for recombinant tissue plasminogen activator (tPA) is within 3 hrs of stroke onset, which significantly limits its clinical applications...
  36. STRUCTURE-FUNCTION STUDIES ON PLASMINOGEN AND PLASMIN
    Francis Castellino; Fiscal Year: 1990
    ..enzymology, immunochemistry, spectroscopic properties and molecular biology of human plasminogen, tissue plasminogen activator, urokinase, streptokinase and fibrin(ogen)...
  37. Combinatorial Peptide Libraries for Biodegradable Linkers to Decrease Normal Tiss
    Kit Lam; Fiscal Year: 2004
    ..combinatorial peptide library method will be used to discover highly specific peptide substrates for tissue plasminogen activator (serine protease (TNKase(R), Activase(R))) to develop an "on-demand-cleavable" linker...
  38. STRUCTURE-FUNCTION STUDIES ON PLASMINOGEN AND PLASMIN
    Francis Castellino; Fiscal Year: 1991
    ..enzymology, immunochemistry, spectroscopic properties and molecular biology of human plasminogen, tissue plasminogen activator, urokinase, streptokinase and fibrin(ogen)...
  39. NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORS
    Stephen Traynelis; Fiscal Year: 2003
    ..serine protease-signaling systems, including precursors to the proteases, thrombin, plasmin, Factor Xa, tissue plasminogen activator (tPaA),urokinase, as well as the brain specific proteases and serpin protease inhibitors...
  40. NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORS
    Stephen Traynelis; Fiscal Year: 2002
    ..serine protease-signaling systems, including precursors to the proteases, thrombin, plasmin, Factor Xa, tissue plasminogen activator (tPaA),urokinase, as well as the brain specific proteases and serpin protease inhibitors...
  41. NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORS
    Stephen Traynelis; Fiscal Year: 2000
    ..serine protease-signaling systems, including precursors to the proteases, thrombin, plasmin, Factor Xa, tissue plasminogen activator (tPaA),urokinase, as well as the brain specific proteases and serpin protease inhibitors...
  42. NMDA RECEPTOR FUNCTION BY SERINE PROTEASE RECEPTORS
    Stephen Traynelis; Fiscal Year: 2001
    ..serine protease-signaling systems, including precursors to the proteases, thrombin, plasmin, Factor Xa, tissue plasminogen activator (tPaA),urokinase, as well as the brain specific proteases and serpin protease inhibitors...
  43. Cardiovascular Effects of Scutellaria baicelensis
    Chun Su Yuan; Fiscal Year: 2001
    ..separate studies, we observed that quercetin, a plant flavonoid, inhibited endothelin-1 and stimulated tissue plasminogen activator in vascular endothelial cells...
  44. Cardiovascular Effects of Scutellaria baicelensis
    Chun Su Yuan; Fiscal Year: 2002
    ..separate studies, we observed that quercetin, a plant flavonoid, inhibited endothelin-1 and stimulated tissue plasminogen activator in vascular endothelial cells...
  45. PEPTIDE MEDIATED ENHANCEMENT OF THROMBOLYSIS
    Daniel Lawrence; Fiscal Year: 1999
    ..PAI-1 may also play a major role in the clinical response to thrombolytic therapy with tissue plasminogen activator (tPA)...
  46. Stroke Therapy
    VINOD D LABHASETWAR; Fiscal Year: 2010
    ..Intravenous administration of tissue plasminogen activator (t-PA) is the only FDA-approved therapy to re-establish cerebral blood flow...
  47. Pulmonary Formulation of tPA for Plastic Bronchitis
    Kathleen A Stringer; Fiscal Year: 2010
    ..Presently, PB is anecdotally treated with inhaled tissue plasminogen activator (tPA) with no evidence for safety or efficacy...
  48. PEPTIDE DEGRADATION IN POLYMER MATRICES
    Richard Schowen; Fiscal Year: 1999
    ..from Investigator's Abstract): Peptide and polypeptide drugs such as interferons, immunoconjugates, tissue plasminogen activator, human growth hormone, and erythropoietin, made available by the biotechnological revolution, are now ..
  49. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 1999
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  50. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 2000
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  51. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 2002
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  52. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 2001
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  53. REGULATION OF BRAIN THROMBOSIS IN STROKE MODELS
    Berislav Zlokovic; Fiscal Year: 2003
    ..APC was protective in this thromboembolic model in wild type mice and in hypercoagulable mice lacking tissue plasminogen activator (tPA-/-)...
  54. CYSTEINYL-RICH DOMAIN IN BLOOD CLOTTING FACTORS
    James Tam; Fiscal Year: 1990
    ..in the blood coagulation pathway, we propose to study the Ca2+- binding activity, the activation of tissue plasminogen activator and urokinase, and the inhibition of binding of Factor IX to its endothelial cell receptor on the ..
  55. DIFFERENTIALLY EXPRESSED GENES IN PRIMARY BREAST CANCER
    ARTHUR PARDEE; Fiscal Year: 1999
    ..protease inhibitor) acts as a tumor suppressor through its interaction with the serine protease, tissue plasminogen activator. The structure of maspin, deduced from its sequence, does not support a strong prediction concerning ..
  56. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 2001
    ..include the plasminogen activator system, which consists of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), balanced by plasminogen activator inhibitor-1 (PAI-1), which limits plasmin generation and ..
  57. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 2000
    ..include the plasminogen activator system, which consists of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), balanced by plasminogen activator inhibitor-1 (PAI-1), which limits plasmin generation and ..
  58. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 2002
    ..include the plasminogen activator system, which consists of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), balanced by plasminogen activator inhibitor-1 (PAI-1), which limits plasmin generation and ..
  59. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 1999
    ..include the plasminogen activator system, which consists of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), balanced by plasminogen activator inhibitor-1 (PAI-1), which limits plasmin generation and ..
  60. A Novel Ultrasound Phased Array and Sonication Method for Stroke Treatments
    Kullervo Hynynen; Fiscal Year: 2010
    ..of patients that will have recanalization of the occluded vessel when administrated together with tissue plasminogen activator (tPA)...
  61. DDAVP IN CONGENITAL PLATELET FUNCTION DISORDERS
    A Rao; Fiscal Year: 1990
    ..factor VIII-related antigen, factor VIII-von Willebrand factor/ristocetin cofactor activity and tissue plasminogen activator (t-PA) in well-characterized patients with congenital platelet function defects, excluding vWD, and 2) ..
  62. A Novel Ultrasound Phased Array and Sonication Method for Stroke Treatments
    Kullervo Hynynen; Fiscal Year: 2009
    ..of patients that will have recanalization of the occluded vessel when administrated together with tissue plasminogen activator (tPA)...
  63. CEREBRAL HEMORRHAGE MODEL--MECHANISMS AND TREATMENTS
    Kenneth Wagner; Fiscal Year: 1999
    ..The delayed edema can be markedly reduced, even prevented, by early (4h) lysis of the clot with tissue plasminogen activator (tPA) followed by hematoma aspiration...
  64. ENHANCING THROMBOLYSIS BY INHIBITION OF A2-ANTIPLASMIN
    Guy Reed; Fiscal Year: 1990
    ..By inhibiting alpha2AP this antibody is synergistic with tissue plasminogen activator (t-PA) in clot lysis; at the same time, it increases the specificity of t-PA for fibrinolysis...
  65. EFFECTS OF 2,3,7,8-TCDD ON ESTROGENIC RESPONSES
    Stephen Safe; Fiscal Year: 1993
    ..foci formation, secretion of the 34-, 52- and 160-kDa proteins, progesterone receptor levels and tissue plasminogen activator activity...
  66. THE RELATIONSHIP OF SERUM PROTEINS TO STROKE SEVERITY
    Edward Jauch; Fiscal Year: 2002
    The approval of tissue plasminogen activator (tPA) for use in acute ischemic stroke by the FDA in 1996 dramatically changed the treatment of stroke...
  67. Structure-Function Studies of Annexin I and II
    Hartmut Luecke; Fiscal Year: 2004
    ..of endothelial cells as a component of the fibrinolysis machinery where it is thought to colocalize tissue plasminogen activator (t-PA) and plasminogen...
  68. Structure-Function Studies of Annexin I and II
    Hartmut Luecke; Fiscal Year: 2005
    ..of endothelial cells as a component of the fibrinolysis machinery where it is thought to colocalize tissue plasminogen activator (t-PA) and plasminogen...
  69. THROMBOLYSIS IN MYOCARDIAL ISCHEMIA COORDINATING CENTER
    Genell Knatterud; Fiscal Year: 1990
    ..TIMI III A is a double-blind comparison of recombinant tissue plasminogen activator (t-PA) to placebo for improvement of coronary artery stenosis and perfusion...
  70. TISSUE PLASMINOGEN ACTIVATOR BINDING TO ANNEXIN II TAIL DOMAIN DIRECT MODULATION
    KATHERINE HAJJAR; Fiscal Year: 1999
    b>Tissue plasminogen activator binds to endothelial cells via the calcium-regulated phospholipid-binding protein annexin II, an interaction that is inhibited by the prothrombotic amino acid homocysteine...